메뉴 건너뛰기




Volumn 36, Issue 11, 2016, Pages 1563-1579

Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?

Author keywords

genetics; insulin resistance; nonalcoholic fatty liver disease; pathophysiology; type 2 diabetes

Indexed keywords

ADIPONECTIN; CHYLOMICRON; FATTY ACID SYNTHASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FKHR;

EID: 84977139059     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13185     Document Type: Review
Times cited : (141)

References (136)
  • 1
    • 0036302288 scopus 로고    scopus 로고
    • Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
    • Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40.
    • (2002) Gastroenterology , vol.123 , pp. 134-140
    • Bugianesi, E.1    Leone, N.2    Vanni, E.3
  • 2
    • 84890562275 scopus 로고    scopus 로고
    • Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
    • Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110–7.
    • (2014) J Hepatol , vol.60 , pp. 110-117
    • Dyson, J.1    Jaques, B.2    Chattopadyhay, D.3
  • 3
    • 80053581540 scopus 로고    scopus 로고
    • Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States
    • Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249–53.
    • (2011) Gastroenterology , vol.141 , pp. 1249-1253
    • Charlton, M.R.1    Burns, J.M.2    Pedersen, R.A.3
  • 4
    • 0037221394 scopus 로고    scopus 로고
    • Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States
    • Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71–9.
    • (2003) Gastroenterology , vol.124 , pp. 71-79
    • Ruhl, C.E.1    Everhart, J.E.2
  • 5
    • 10644220306 scopus 로고    scopus 로고
    • Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity
    • Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–95.
    • (2004) Hepatology , vol.40 , pp. 1387-1395
    • Browning, J.D.1    Szczepaniak, L.S.2    Dobbins, R.3
  • 6
    • 84983123731 scopus 로고    scopus 로고
    • Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups
    • Non-Alcoholic Fatty Liver Disease Study G, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015; 47: 997–1006.
    • (2015) Dig Liver Dis , vol.47 , pp. 997-1006
    • Lonardo, A.1    Bellentani, S.2    Argo, C.K.3    Ballestri, S.4    Byrne, C.D.5
  • 7
    • 0033231294 scopus 로고    scopus 로고
    • Association of nonalcoholic fatty liver disease with insulin resistance
    • Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5.
    • (1999) Am J Med , vol.107 , pp. 450-455
    • Marchesini, G.1    Brizi, M.2    Morselli-Labate, A.M.3
  • 8
    • 0035431018 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease: a feature of the metabolic syndrome
    • Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844–50.
    • (2001) Diabetes , vol.50 , pp. 1844-1850
    • Marchesini, G.1    Brizi, M.2    Bianchi, G.3
  • 9
    • 0037382786 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
    • Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–23.
    • (2003) Hepatology , vol.37 , pp. 917-923
    • Marchesini, G.1    Bugianesi, E.2    Forlani, G.3
  • 10
    • 84921487729 scopus 로고    scopus 로고
    • Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
    • Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61: 506–14.
    • (2015) Hepatology , vol.61 , pp. 506-514
    • Dongiovanni, P.1    Petta, S.2    Maglio, C.3
  • 11
    • 84927615859 scopus 로고    scopus 로고
    • Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors
    • Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014; 20: 12945–55.
    • (2014) World J Gastroenterol , vol.20 , pp. 12945-12955
    • Dongiovanni, P.1    Romeo, S.2    Valenti, L.3
  • 12
    • 84991797701 scopus 로고    scopus 로고
    • The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?
    • Dongiovanni P, Rametta R, Meroni M, Valenti L. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target? Expert Rev Gastroenterol Hepatol 2015; 10: 1–14.
    • (2015) Expert Rev Gastroenterol Hepatol , vol.10 , pp. 1-14
    • Dongiovanni, P.1    Rametta, R.2    Meroni, M.3    Valenti, L.4
  • 13
    • 84902672359 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
    • Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901–10.
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 901-910
    • Yki-Jarvinen, H.1
  • 14
    • 0024160877 scopus 로고
    • Banting lecture 1988. Role of insulin resistance in human disease
    • Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
    • (1988) Diabetes , vol.37 , pp. 1595-1607
    • Reaven, G.M.1
  • 15
    • 84918819322 scopus 로고    scopus 로고
    • Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease
    • Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014; 371: 1131–41.
    • (2014) N Engl J Med , vol.371 , pp. 1131-1141
    • Shulman, G.I.1
  • 16
    • 0034072554 scopus 로고    scopus 로고
    • Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans
    • Roden M, Stingl H, Chandramouli V, et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 2000; 49: 701–7.
    • (2000) Diabetes , vol.49 , pp. 701-707
    • Roden, M.1    Stingl, H.2    Chandramouli, V.3
  • 17
    • 0033890616 scopus 로고    scopus 로고
    • Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study
    • Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000; 49: 1367–73.
    • (2000) Diabetes , vol.49 , pp. 1367-1373
    • Gastaldelli, A.1    Baldi, S.2    Pettiti, M.3
  • 18
    • 0042320958 scopus 로고    scopus 로고
    • Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans
    • Adkins A, Basu R, Persson M, et al. Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans. Diabetes 2003; 52: 2213–20.
    • (2003) Diabetes , vol.52 , pp. 2213-2220
    • Adkins, A.1    Basu, R.2    Persson, M.3
  • 19
    • 65549151428 scopus 로고    scopus 로고
    • The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans
    • Kantartzis K, Machicao F, Machann J, et al. The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin Sci 2009; 116: 531–7.
    • (2009) Clin Sci , vol.116 , pp. 531-537
    • Kantartzis, K.1    Machicao, F.2    Machann, J.3
  • 20
    • 0036312905 scopus 로고    scopus 로고
    • Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men
    • Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023–8.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 3023-3028
    • Seppala-Lindroos, A.1    Vehkavaara, S.2    Hakkinen, A.M.3
  • 21
    • 20944450486 scopus 로고    scopus 로고
    • Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
    • Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634–42.
    • (2005) Diabetologia , vol.48 , pp. 634-642
    • Bugianesi, E.1    Gastaldelli, A.2    Vanni, E.3
  • 22
    • 64649104158 scopus 로고    scopus 로고
    • Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
    • Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773–95.
    • (2009) Diabetes , vol.58 , pp. 773-795
    • Defronzo, R.A.1
  • 23
    • 84908254009 scopus 로고    scopus 로고
    • beta-Cell function in type 2 diabetes
    • Ferrannini E, Mari A. beta-Cell function in type 2 diabetes. Metabolism 2014; 63: 1217–27.
    • (2014) Metabolism , vol.63 , pp. 1217-1227
    • Ferrannini, E.1    Mari, A.2
  • 24
    • 18244382304 scopus 로고    scopus 로고
    • Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
    • Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–51.
    • (2005) J Clin Invest , vol.115 , pp. 1343-1351
    • Donnelly, K.L.1    Smith, C.I.2    Schwarzenberg, S.J.3
  • 25
    • 77957375969 scopus 로고    scopus 로고
    • Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
    • Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341–50.
    • (2010) N Engl J Med , vol.363 , pp. 1341-1350
    • Targher, G.1    Day, C.P.2    Bonora, E.3
  • 26
    • 70349326750 scopus 로고    scopus 로고
    • Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
    • Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430–5.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 15430-15435
    • Fabbrini, E.1    Magkos, F.2    Mohammed, B.S.3
  • 27
    • 34547514221 scopus 로고    scopus 로고
    • Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects
    • Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496–506.
    • (2007) Gastroenterology , vol.133 , pp. 496-506
    • Gastaldelli, A.1    Cusi, K.2    Pettiti, M.3
  • 28
    • 84877854022 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease
    • Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5: 1544–60.
    • (2013) Nutrients , vol.5 , pp. 1544-1560
    • Gaggini, M.1    Morelli, M.2    Buzzigoli, E.3
  • 29
    • 0034033372 scopus 로고    scopus 로고
    • Visceral fat and insulin resistance–causative or correlative?
    • Frayn KN. Visceral fat and insulin resistance–causative or correlative? Br J Nutr 2000; 83(Suppl. 1): S71–7.
    • (2000) Br J Nutr , vol.83 , pp. S71-S77
    • Frayn, K.N.1
  • 30
    • 84860420859 scopus 로고    scopus 로고
    • Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus
    • Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 93(Suppl. 1): S60–5.
    • (2011) Diabetes Res Clin Pract , vol.93 , pp. S60-S65
    • Gastaldelli, A.1
  • 31
    • 18844432308 scopus 로고    scopus 로고
    • Adiponectin and adiponectin receptors
    • Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439–51.
    • (2005) Endocr Rev , vol.26 , pp. 439-451
    • Kadowaki, T.1    Yamauchi, T.2
  • 32
    • 79951810722 scopus 로고    scopus 로고
    • Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
    • Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313–26.
    • (2011) Metabolism , vol.60 , pp. 313-326
    • Polyzos, S.A.1    Toulis, K.A.2    Goulis, D.G.3    Zavos, C.4    Kountouras, J.5
  • 33
    • 70349238777 scopus 로고    scopus 로고
    • Adipokines in liver diseases
    • Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957–69.
    • (2009) Hepatology , vol.50 , pp. 957-969
    • Marra, F.1    Bertolani, C.2
  • 34
    • 0025740427 scopus 로고
    • Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis
    • Petrides AS, Groop LC, Riely CA, Defronzo RA. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest 1991; 88: 561–70.
    • (1991) J Clin Invest , vol.88 , pp. 561-570
    • Petrides, A.S.1    Groop, L.C.2    Riely, C.A.3    Defronzo, R.A.4
  • 35
    • 39049102073 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients
    • Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444–50.
    • (2008) Diabetologia , vol.51 , pp. 444-450
    • Targher, G.1    Bertolini, L.2    Rodella, S.3
  • 36
    • 84939200165 scopus 로고    scopus 로고
    • Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis
    • Dongiovanni P, Romeo S, Valenti L. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int 2015; 2015: 460190.
    • (2015) Biomed Res Int , vol.2015 , pp. 460190
    • Dongiovanni, P.1    Romeo, S.2    Valenti, L.3
  • 37
    • 0037267345 scopus 로고    scopus 로고
    • The association of fatty liver and diabetes risk
    • Okamoto M, Takeda Y, Yoda Y, et al. The association of fatty liver and diabetes risk. J Epidemiol 2003; 13: 15–21.
    • (2003) J Epidemiol , vol.13 , pp. 15-21
    • Okamoto, M.1    Takeda, Y.2    Yoda, Y.3
  • 38
    • 34347402532 scopus 로고    scopus 로고
    • Effects of nonalcoholic fatty liver disease on the development of metabolic disorders
    • Fan JG, Li F, Cai XB, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007; 22: 1086–91.
    • (2007) J Gastroenterol Hepatol , vol.22 , pp. 1086-1091
    • Fan, J.G.1    Li, F.2    Cai, X.B.3
  • 39
    • 36048934639 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men
    • Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30: 2940–4.
    • (2007) Diabetes Care , vol.30 , pp. 2940-2944
    • Shibata, M.1    Kihara, Y.2    Taguchi, M.3    Tashiro, M.4    Otsuki, M.5
  • 40
    • 41749083027 scopus 로고    scopus 로고
    • Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults
    • Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008; 25: 476–81.
    • (2008) Diabet Med , vol.25 , pp. 476-481
    • Kim, C.H.1    Park, J.Y.2    Lee, K.U.3    Kim, J.H.4    Kim, H.K.5
  • 41
    • 76149092159 scopus 로고    scopus 로고
    • Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup
    • Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25: 352–6.
    • (2010) J Gastroenterol Hepatol , vol.25 , pp. 352-356
    • Yamada, T.1    Fukatsu, M.2    Suzuki, S.3
  • 42
    • 79956074978 scopus 로고    scopus 로고
    • Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study
    • Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011; 34: 727–9.
    • (2011) Diabetes Care , vol.34 , pp. 727-729
    • Bae, J.C.1    Rhee, E.J.2    Lee, W.Y.3
  • 43
    • 84876105171 scopus 로고    scopus 로고
    • Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study
    • Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013; 57: 1378–83.
    • (2013) Hepatology , vol.57 , pp. 1378-1383
    • Park, S.K.1    Seo, M.H.2    Shin, H.C.3    Ryoo, J.H.4
  • 44
    • 84862075971 scopus 로고    scopus 로고
    • Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes
    • Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35: 717–22.
    • (2012) Diabetes Care , vol.35 , pp. 717-722
    • Sung, K.C.1    Jeong, W.S.2    Wild, S.H.3    Byrne, C.D.4
  • 45
    • 84871643501 scopus 로고    scopus 로고
    • Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus
    • Kasturiratne A, Weerasinghe S, Dassanayake AS, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013; 28: 142–7.
    • (2013) J Gastroenterol Hepatol , vol.28 , pp. 142-147
    • Kasturiratne, A.1    Weerasinghe, S.2    Dassanayake, A.S.3
  • 46
    • 84889658153 scopus 로고    scopus 로고
    • Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population
    • Chang Y, Jung HS, Yun KE, et al. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013; 108: 1861–8.
    • (2013) Am J Gastroenterol , vol.108 , pp. 1861-1868
    • Chang, Y.1    Jung, H.S.2    Yun, K.E.3
  • 47
    • 84883686923 scopus 로고    scopus 로고
    • Resolution of fatty liver and risk of incident diabetes
    • Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013; 98: 3637–43.
    • (2013) J Clin Endocrinol Metab , vol.98 , pp. 3637-3643
    • Sung, K.C.1    Wild, S.H.2    Byrne, C.D.3
  • 48
    • 84962469252 scopus 로고    scopus 로고
    • Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of Type 2 diabetes
    • Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of Type 2 diabetes. Diabetes Care 2015; 38: 1673–9.
    • (2015) Diabetes Care , vol.38 , pp. 1673-1679
    • Yamazaki, H.1    Tsuboya, T.2    Tsuji, K.3    Dohke, M.4    Maguchi, H.5
  • 49
    • 84955489581 scopus 로고    scopus 로고
    • The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals
    • Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016; 36: 275–83.
    • (2016) Liver Int , vol.36 , pp. 275-283
    • Fukuda, T.1    Hamaguchi, M.2    Kojima, T.3
  • 50
    • 84937858836 scopus 로고    scopus 로고
    • Liver fat, statin use, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis
    • Shah RV, Allison MA, Lima JA, et al. Liver fat, statin use, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2015; 242: 211–7.
    • (2015) Atherosclerosis , vol.242 , pp. 211-217
    • Shah, R.V.1    Allison, M.A.2    Lima, J.A.3
  • 51
    • 84945447081 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study
    • Ming J, Xu S, Gao B, et al. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study. Liver Int 2015; 35: 2401–7.
    • (2015) Liver Int , vol.35 , pp. 2401-2407
    • Ming, J.1    Xu, S.2    Gao, B.3
  • 52
    • 84940121986 scopus 로고    scopus 로고
    • Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus
    • Li WD, Fu KF, Li GM, et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J Gastroenterol 2015; 21: 9607–13.
    • (2015) World J Gastroenterol , vol.21 , pp. 9607-9613
    • Li, W.D.1    Fu, K.F.2    Li, G.M.3
  • 53
    • 84875259571 scopus 로고    scopus 로고
    • Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study
    • Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013; 44: 115–20.
    • (2013) Arch Med Res , vol.44 , pp. 115-120
    • Choi, J.H.1    Rhee, E.J.2    Bae, J.C.3
  • 54
    • 84964510429 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
    • Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31: 936–44.
    • (2016) J Gastroenterol Hepatol , vol.31 , pp. 936-944
    • Ballestri, S.1    Zona, S.2    Targher, G.3
  • 55
    • 33750606061 scopus 로고    scopus 로고
    • Long-term follow-up of patients with NAFLD and elevated liver enzymes
    • Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–73.
    • (2006) Hepatology , vol.44 , pp. 865-873
    • Ekstedt, M.1    Franzen, L.E.2    Mathiesen, U.L.3
  • 56
    • 77954956697 scopus 로고    scopus 로고
    • Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance
    • Savage DB, Semple RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 2010; 21: 329–36.
    • (2010) Curr Opin Lipidol , vol.21 , pp. 329-336
    • Savage, D.B.1    Semple, R.K.2
  • 57
    • 84862023939 scopus 로고    scopus 로고
    • Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression
    • Haas JT, Miao J, Chanda D, et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab 2012; 15: 873–84.
    • (2012) Cell Metab , vol.15 , pp. 873-884
    • Haas, J.T.1    Miao, J.2    Chanda, D.3
  • 58
    • 62749188867 scopus 로고    scopus 로고
    • The role of the lipogenic pathway in the development of hepatic steatosis
    • Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008; 34(Pt 2): 643–8.
    • (2008) Diabetes Metab , vol.34 , pp. 643-648
    • Postic, C.1    Girard, J.2
  • 59
    • 0036251153 scopus 로고    scopus 로고
    • SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
    • Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–31.
    • (2002) J Clin Invest , vol.109 , pp. 1125-1131
    • Horton, J.D.1    Goldstein, J.L.2    Brown, M.S.3
  • 60
    • 79961165137 scopus 로고    scopus 로고
    • mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway
    • Peterson TR, Sengupta SS, Harris TE, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146: 408–20.
    • (2011) Cell , vol.146 , pp. 408-420
    • Peterson, T.R.1    Sengupta, S.S.2    Harris, T.E.3
  • 61
    • 50049116472 scopus 로고    scopus 로고
    • SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
    • Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008; 8: 224–36.
    • (2008) Cell Metab , vol.8 , pp. 224-236
    • Porstmann, T.1    Santos, C.R.2    Griffiths, B.3
  • 62
    • 35248816945 scopus 로고    scopus 로고
    • The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes
    • Brown NF, Stefanovic-Racic M, Sipula IJ, Perdomo G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 2007; 56: 1500–7.
    • (2007) Metabolism , vol.56 , pp. 1500-1507
    • Brown, N.F.1    Stefanovic-Racic, M.2    Sipula, I.J.3    Perdomo, G.4
  • 63
    • 79959996153 scopus 로고    scopus 로고
    • Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways
    • Yecies JL, Zhang HH, Menon S, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 2011; 14: 21–32.
    • (2011) Cell Metab , vol.14 , pp. 21-32
    • Yecies, J.L.1    Zhang, H.H.2    Menon, S.3
  • 64
    • 77649264504 scopus 로고    scopus 로고
    • Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis
    • Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010; 107: 3441–6.
    • (2010) Proc Natl Acad Sci USA , vol.107 , pp. 3441-3446
    • Li, S.1    Brown, M.S.2    Goldstein, J.L.3
  • 65
    • 33244464562 scopus 로고    scopus 로고
    • Critical nodes in signalling pathways: insights into insulin action
    • Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85–96.
    • (2006) Nat Rev Mol Cell Biol , vol.7 , pp. 85-96
    • Taniguchi, C.M.1    Emanuelli, B.2    Kahn, C.R.3
  • 66
    • 84857934301 scopus 로고    scopus 로고
    • Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1
    • Lu M, Wan M, Leavens KF, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med 2012; 18: 388–95.
    • (2012) Nat Med , vol.18 , pp. 388-395
    • Lu, M.1    Wan, M.2    Leavens, K.F.3
  • 67
    • 79959962745 scopus 로고    scopus 로고
    • Hormonal regulation of hepatic glucose production in health and disease
    • Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab 2011; 14: 9–19.
    • (2011) Cell Metab , vol.14 , pp. 9-19
    • Lin, H.V.1    Accili, D.2
  • 68
    • 0035185021 scopus 로고    scopus 로고
    • The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression
    • Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001; 108: 1359–67.
    • (2001) J Clin Invest , vol.108 , pp. 1359-1367
    • Nakae, J.1    Kitamura, T.2    Silver, D.L.3    Accili, D.4
  • 69
    • 20144365700 scopus 로고    scopus 로고
    • Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes
    • Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005; 280: 20589–95.
    • (2005) J Biol Chem , vol.280 , pp. 20589-20595
    • Frescas, D.1    Valenti, L.2    Accili, D.3
  • 70
    • 0034680839 scopus 로고    scopus 로고
    • Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity
    • Schmoll D, Walker KS, Alessi DR, et al. Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity. J Biol Chem 2000; 275: 36324–33.
    • (2000) J Biol Chem , vol.275 , pp. 36324-36333
    • Schmoll, D.1    Walker, K.S.2    Alessi, D.R.3
  • 71
    • 33744515637 scopus 로고    scopus 로고
    • FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression
    • Zhang W, Patil S, Chauhan B, et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 2006; 281: 10105–17.
    • (2006) J Biol Chem , vol.281 , pp. 10105-10117
    • Zhang, W.1    Patil, S.2    Chauhan, B.3
  • 72
    • 0029859045 scopus 로고    scopus 로고
    • Regulation of gene expression by insulin
    • O'Brien RM, Granner DK. Regulation of gene expression by insulin. Physiol Rev 1996; 76: 1109–61.
    • (1996) Physiol Rev , vol.76 , pp. 1109-1161
    • O'Brien, R.M.1    Granner, D.K.2
  • 73
    • 79961173038 scopus 로고    scopus 로고
    • Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner
    • Pajvani UB, Shawber CJ, Samuel VT, et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med 2011; 17: 961–7.
    • (2011) Nat Med , vol.17 , pp. 961-967
    • Pajvani, U.B.1    Shawber, C.J.2    Samuel, V.T.3
  • 74
    • 84882245596 scopus 로고    scopus 로고
    • Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability
    • Pajvani UB, Qiang L, Kangsamaksin T, et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 2013; 19: 1054–60.
    • (2013) Nat Med , vol.19 , pp. 1054-1060
    • Pajvani, U.B.1    Qiang, L.2    Kangsamaksin, T.3
  • 75
    • 84862909028 scopus 로고    scopus 로고
    • Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice
    • Zhang K, Li L, Qi Y, et al. Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology 2012; 153: 631–46.
    • (2012) Endocrinology , vol.153 , pp. 631-646
    • Zhang, K.1    Li, L.2    Qi, Y.3
  • 76
    • 79954576666 scopus 로고    scopus 로고
    • Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene
    • Tao R, Wei D, Gao H, et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem 2011; 286: 14681–90.
    • (2011) J Biol Chem , vol.286 , pp. 14681-14690
    • Tao, R.1    Wei, D.2    Gao, H.3
  • 77
    • 84922754155 scopus 로고    scopus 로고
    • Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors
    • Haeusler RA, Hartil K, Vaitheesvaran B, et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun 2014; 5: 5190.
    • (2014) Nat Commun , vol.5 , pp. 5190
    • Haeusler, R.A.1    Hartil, K.2    Vaitheesvaran, B.3
  • 78
    • 71449091240 scopus 로고    scopus 로고
    • Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin
    • Liu HY, Han J, Cao SY, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem 2009; 284: 31484–92.
    • (2009) J Biol Chem , vol.284 , pp. 31484-31492
    • Liu, H.Y.1    Han, J.2    Cao, S.Y.3
  • 79
    • 84879010418 scopus 로고    scopus 로고
    • S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice: lipids as usual suspects
    • Ceuninck FD, Kargar C, Charton Y, et al. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice: lipids as usual suspects. Br J Pharmacol 2013; 169: 999–1010.
    • (2013) Br J Pharmacol , vol.169 , pp. 999-1010
    • Ceuninck, F.D.1    Kargar, C.2    Charton, Y.3
  • 80
    • 84871604441 scopus 로고    scopus 로고
    • Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans
    • De Ceuninck F, Kargar C, Ilic C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2013; 168: 339–53.
    • (2013) Br J Pharmacol , vol.168 , pp. 339-353
    • De Ceuninck, F.1    Kargar, C.2    Ilic, C.3
  • 81
    • 13844312400 scopus 로고    scopus 로고
    • Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
    • Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098–101.
    • (2005) Science , vol.307 , pp. 1098-1101
    • Sarbassov, D.D.1    Guertin, D.A.2    Ali, S.M.3    Sabatini, D.M.4
  • 83
    • 15944406764 scopus 로고    scopus 로고
    • PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth
    • Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18: 13–24.
    • (2005) Mol Cell , vol.18 , pp. 13-24
    • Gao, T.1    Furnari, F.2    Newton, A.C.3
  • 84
    • 33947203621 scopus 로고    scopus 로고
    • PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms
    • Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007; 25: 917–31.
    • (2007) Mol Cell , vol.25 , pp. 917-931
    • Brognard, J.1    Sierecki, E.2    Gao, T.3    Newton, A.C.4
  • 86
    • 84898961798 scopus 로고    scopus 로고
    • PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice
    • e10.
    • Li X, Stevens PD, Liu J, et al. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology 2014; 146: 1301–12.e10.
    • (2014) Gastroenterology , vol.146 , pp. 1301-1312
    • Li, X.1    Stevens, P.D.2    Liu, J.3
  • 87
    • 84899459754 scopus 로고    scopus 로고
    • Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor beta-activated stem cells
    • Ghalali A, Ye ZW, Hogberg J, Stenius U. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor beta-activated stem cells. J Biol Chem 2014; 289: 11601–15.
    • (2014) J Biol Chem , vol.289 , pp. 11601-11615
    • Ghalali, A.1    Ye, Z.W.2    Hogberg, J.3    Stenius, U.4
  • 88
    • 84899821715 scopus 로고    scopus 로고
    • Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt
    • Wang P, Zhou Z, Hu A, et al. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell 2014; 54: 378–91.
    • (2014) Mol Cell , vol.54 , pp. 378-391
    • Wang, P.1    Zhou, Z.2    Hu, A.3
  • 89
    • 84953932016 scopus 로고    scopus 로고
    • mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2
    • Kim K, Qiang L, Hayden MS, et al. mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2. Nat Commun 2016; 7: 10255.
    • (2016) Nat Commun , vol.7 , pp. 10255
    • Kim, K.1    Qiang, L.2    Hayden, M.S.3
  • 90
    • 79952312698 scopus 로고    scopus 로고
    • Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma
    • Calvisi DF, Wang C, Ho C, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011; 140: 1071–83.
    • (2011) Gastroenterology , vol.140 , pp. 1071-1083
    • Calvisi, D.F.1    Wang, C.2    Ho, C.3
  • 91
    • 84884402458 scopus 로고    scopus 로고
    • SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice
    • Li L, Wang C, Calvisi DF, et al. SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice. PLoS ONE 2013; 8: e75104.
    • (2013) PLoS ONE , vol.8
    • Li, L.1    Wang, C.2    Calvisi, D.F.3
  • 92
    • 84860454425 scopus 로고    scopus 로고
    • Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c
    • Hagiwara A, Cornu M, Cybulski N, et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 2012; 15: 725–38.
    • (2012) Cell Metab , vol.15 , pp. 725-738
    • Hagiwara, A.1    Cornu, M.2    Cybulski, N.3
  • 93
    • 70249108137 scopus 로고    scopus 로고
    • The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis
    • Guo S, Copps KD, Dong X, et al. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 2009; 29: 5070–83.
    • (2009) Mol Cell Biol , vol.29 , pp. 5070-5083
    • Guo, S.1    Copps, K.D.2    Dong, X.3
  • 94
    • 70350417158 scopus 로고    scopus 로고
    • Akt2 is required for hepatic lipid accumulation in models of insulin resistance
    • Leavens KF, Easton RM, Shulman GI, Previs SF, Birnbaum MJ. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab 2009; 10: 405–18.
    • (2009) Cell Metab , vol.10 , pp. 405-418
    • Leavens, K.F.1    Easton, R.M.2    Shulman, G.I.3    Previs, S.F.4    Birnbaum, M.J.5
  • 95
    • 84930216520 scopus 로고    scopus 로고
    • Pathogenesis of selective insulin resistance in isolated hepatocytes
    • Cook JR, Langlet F, Kido Y, Accili D. Pathogenesis of selective insulin resistance in isolated hepatocytes. J Biol Chem 2015; 290: 13972–80.
    • (2015) J Biol Chem , vol.290 , pp. 13972-13980
    • Cook, J.R.1    Langlet, F.2    Kido, Y.3    Accili, D.4
  • 96
    • 80052947518 scopus 로고    scopus 로고
    • NASH animal models: are we there yet?
    • Kohli R, Feldstein AE. NASH animal models: are we there yet? J Hepatol 2011; 55: 941–3.
    • (2011) J Hepatol , vol.55 , pp. 941-943
    • Kohli, R.1    Feldstein, A.E.2
  • 97
    • 50049097587 scopus 로고    scopus 로고
    • Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet
    • Rinella ME, Elias MS, Smolak RR, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 2008; 49: 1068–76.
    • (2008) J Lipid Res , vol.49 , pp. 1068-1076
    • Rinella, M.E.1    Elias, M.S.2    Smolak, R.R.3
  • 98
    • 45749114635 scopus 로고    scopus 로고
    • Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis
    • Valenti L, Rametta R, Dongiovanni P, et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008; 57: 1355–62.
    • (2008) Diabetes , vol.57 , pp. 1355-1362
    • Valenti, L.1    Rametta, R.2    Dongiovanni, P.3
  • 99
    • 84880255942 scopus 로고    scopus 로고
    • Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects
    • Rametta R, Mozzi E, Dongiovanni P, et al. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. Int J Obes 2013; 37: 986–92.
    • (2013) Int J Obes , vol.37 , pp. 986-992
    • Rametta, R.1    Mozzi, E.2    Dongiovanni, P.3
  • 100
    • 80053627289 scopus 로고    scopus 로고
    • Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
    • Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 2011; 108: 16381–5.
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 16381-16385
    • Kumashiro, N.1    Erion, D.M.2    Zhang, D.3
  • 101
    • 84959104290 scopus 로고    scopus 로고
    • Ceramides dissociate steatosis and insulin resistance in the human liver in non-alcoholic fatty liver disease
    • Luukkonen PK, Zhou Y, Sadevirta S, et al. Ceramides dissociate steatosis and insulin resistance in the human liver in non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1167–75.
    • (2016) J Hepatol , vol.64 , pp. 1167-1175
    • Luukkonen, P.K.1    Zhou, Y.2    Sadevirta, S.3
  • 102
    • 84907984591 scopus 로고    scopus 로고
    • CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance
    • Raichur S, Wang ST, Chan PW, et al. CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab 2014; 20: 687–95.
    • (2014) Cell Metab , vol.20 , pp. 687-695
    • Raichur, S.1    Wang, S.T.2    Chan, P.W.3
  • 103
    • 84890116926 scopus 로고    scopus 로고
    • Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
    • Oresic M, Hyotylainen T, Kotronen A, et al. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia 2013; 56: 2266–74.
    • (2013) Diabetologia , vol.56 , pp. 2266-2274
    • Oresic, M.1    Hyotylainen, T.2    Kotronen, A.3
  • 104
    • 84882959698 scopus 로고    scopus 로고
    • Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver
    • Lehmann R, Franken H, Dammeier S, et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 2013; 36: 2331–8.
    • (2013) Diabetes Care , vol.36 , pp. 2331-2338
    • Lehmann, R.1    Franken, H.2    Dammeier, S.3
  • 105
    • 3142677943 scopus 로고    scopus 로고
    • SREBP-1c mediates the insulin-dependent hepatic glucokinase expression
    • Kim SY, Kim HI, Kim TH, et al. SREBP-1c mediates the insulin-dependent hepatic glucokinase expression. J Biol Chem 2004; 279: 30823–9.
    • (2004) J Biol Chem , vol.279 , pp. 30823-30829
    • Kim, S.Y.1    Kim, H.I.2    Kim, T.H.3
  • 106
    • 79960086105 scopus 로고    scopus 로고
    • Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans
    • Peter A, Stefan N, Cegan A, et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 2011; 96: E1126–30.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. E1126-E1130
    • Peter, A.1    Stefan, N.2    Cegan, A.3
  • 107
    • 84891762279 scopus 로고    scopus 로고
    • Hepatic notch signaling correlates with insulin resistance and nonalcoholic Fatty liver disease
    • Valenti L, Mendoza RM, Rametta R, et al. Hepatic notch signaling correlates with insulin resistance and nonalcoholic Fatty liver disease. Diabetes 2013; 62: 4052–62.
    • (2013) Diabetes , vol.62 , pp. 4052-4062
    • Valenti, L.1    Mendoza, R.M.2    Rametta, R.3
  • 108
    • 84945321040 scopus 로고    scopus 로고
    • Genetics of nonalcoholic fatty liver disease
    • Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016; 65: 1026–37.
    • (2016) Metabolism , vol.65 , pp. 1026-1037
    • Dongiovanni, P.1    Valenti, L.2
  • 109
    • 56749096610 scopus 로고    scopus 로고
    • Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
    • Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–5.
    • (2008) Nat Genet , vol.40 , pp. 1461-1465
    • Romeo, S.1    Kozlitina, J.2    Xing, C.3
  • 110
    • 79957462315 scopus 로고    scopus 로고
    • Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease
    • Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883–94.
    • (2011) Hepatology , vol.53 , pp. 1883-1894
    • Sookoian, S.1    Pirola, C.J.2
  • 111
    • 84887553152 scopus 로고    scopus 로고
    • PNPLA3 I148M polymorphism and progressive liver disease
    • Dongiovanni P, Donati B, Fares R, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19: 6969–78.
    • (2013) World J Gastroenterol , vol.19 , pp. 6969-6978
    • Dongiovanni, P.1    Donati, B.2    Fares, R.3
  • 112
    • 77949895032 scopus 로고    scopus 로고
    • A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis
    • He S, Mcphaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706–15.
    • (2010) J Biol Chem , vol.285 , pp. 6706-6715
    • He, S.1    Mcphaul, C.2    Li, J.Z.3
  • 113
    • 84903996547 scopus 로고    scopus 로고
    • PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
    • Pirazzi C, Valenti L, Motta BM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 2014; 23: 4077–85.
    • (2014) Hum Mol Genet , vol.23 , pp. 4077-4085
    • Pirazzi, C.1    Valenti, L.2    Motta, B.M.3
  • 114
    • 84897430331 scopus 로고    scopus 로고
    • PNPLA3 mediates hepatocyte triacylglycerol remodeling
    • Ruhanen H, Perttila J, Holtta-Vuori M, et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res 2014; 55: 739–46.
    • (2014) J Lipid Res , vol.55 , pp. 739-746
    • Ruhanen, H.1    Perttila, J.2    Holtta-Vuori, M.3
  • 115
    • 84920955177 scopus 로고    scopus 로고
    • Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
    • Smagris E, Basuray S, Li J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61: 108–18.
    • (2015) Hepatology , vol.61 , pp. 108-118
    • Smagris, E.1    Basuray, S.2    Li, J.3
  • 116
    • 84954290324 scopus 로고    scopus 로고
    • The rs2294918 E434K variant modulates PNPLA3 expression and liver damage
    • Donati B, Motta BM, Pingitore P, et al. The rs2294918 E434K variant modulates PNPLA3 expression and liver damage. Hepatology 2016; 63: 787–98.
    • (2016) Hepatology , vol.63 , pp. 787-798
    • Donati, B.1    Motta, B.M.2    Pingitore, P.3
  • 117
    • 84891810442 scopus 로고    scopus 로고
    • Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity
    • Hyysalo J, Gopalacharyulu P, Bian H, et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes 2013; 63: 312–22.
    • (2013) Diabetes , vol.63 , pp. 312-322
    • Hyysalo, J.1    Gopalacharyulu, P.2    Bian, H.3
  • 118
    • 84926660045 scopus 로고    scopus 로고
    • PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans
    • Peter A, Kovarova M, Nadalin S, et al. PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans. Diabetologia 2014; 57: 2103–7.
    • (2014) Diabetologia , vol.57 , pp. 2103-2107
    • Peter, A.1    Kovarova, M.2    Nadalin, S.3
  • 119
    • 84862491622 scopus 로고    scopus 로고
    • Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant
    • Palmer CN, Maglio C, Pirazzi C, et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS ONE 2012; 7: e39362.
    • (2012) PLoS ONE , vol.7
    • Palmer, C.N.1    Maglio, C.2    Pirazzi, C.3
  • 120
    • 84898058711 scopus 로고    scopus 로고
    • Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
    • Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352–6.
    • (2014) Nat Genet , vol.46 , pp. 352-356
    • Kozlitina, J.1    Smagris, E.2    Stender, S.3
  • 121
    • 84902602986 scopus 로고    scopus 로고
    • TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content
    • Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA 2014; 111: 8913–8.
    • (2014) Proc Natl Acad Sci USA , vol.111 , pp. 8913-8918
    • Mahdessian, H.1    Taxiarchis, A.2    Popov, S.3
  • 122
    • 84898058547 scopus 로고    scopus 로고
    • Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk
    • Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46: 345–51.
    • (2014) Nat Genet , vol.46 , pp. 345-351
    • Holmen, O.L.1    Zhang, H.2    Fan, Y.3
  • 123
    • 84969277864 scopus 로고    scopus 로고
    • Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins
    • Smagris E, Gilyard S, Basuray S, Cohen JC, HOBBS HH. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem 2016; 291: 10659–76.
    • (2016) J Biol Chem , vol.291 , pp. 10659-10676
    • Smagris, E.1    Gilyard, S.2    Basuray, S.3    Cohen, J.C.4    Hobbs, H.5
  • 124
    • 84955203053 scopus 로고    scopus 로고
    • The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis
    • Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis. Hepatology 2015; 62: 1742–56.
    • (2015) Hepatology , vol.62 , pp. 1742-1756
    • Pirola, C.J.1    Sookoian, S.2
  • 125
    • 84964334172 scopus 로고    scopus 로고
    • The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent
    • Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 2016; 150: 1219–230.
    • (2016) Gastroenterology , vol.150 , pp. 1219-1230
    • Mancina, R.M.1    Dongiovanni, P.2    Petta, S.3
  • 126
    • 79953745343 scopus 로고    scopus 로고
    • Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits
    • Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
    • (2011) PLoS Genet , vol.7
    • Speliotes, E.K.1    Yerges-Armstrong, L.M.2    Wu, J.3
  • 127
    • 84857398069 scopus 로고    scopus 로고
    • Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents
    • Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2011; 55: 781–9.
    • (2011) Hepatology , vol.55 , pp. 781-789
    • Santoro, N.1    Zhang, C.K.2    Zhao, H.3
  • 128
    • 84896824930 scopus 로고    scopus 로고
    • Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease
    • Petta S, Miele L, Bugianesi E, et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease. PLoS ONE 2014; 9: e87523.
    • (2014) PLoS ONE , vol.9
    • Petta, S.1    Miele, L.2    Bugianesi, E.3
  • 129
    • 84857429794 scopus 로고    scopus 로고
    • Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms
    • Valenti L, Alisi A, Nobili V. Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology 2012; 55: 661–3.
    • (2012) Hepatology , vol.55 , pp. 661-663
    • Valenti, L.1    Alisi, A.2    Nobili, V.3
  • 130
    • 70349980881 scopus 로고    scopus 로고
    • The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver
    • Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009; 18: 4081–8.
    • (2009) Hum Mol Genet , vol.18 , pp. 4081-4088
    • Beer, N.L.1    Tribble, N.D.2    McCulloch, L.J.3
  • 131
    • 84926410232 scopus 로고    scopus 로고
    • Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia
    • Di Filippo M, Moulin P, Roy P, et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J Hepatol 2014; 61: 891–902.
    • (2014) J Hepatol , vol.61 , pp. 891-902
    • Di Filippo, M.1    Moulin, P.2    Roy, P.3
  • 132
    • 84881025772 scopus 로고    scopus 로고
    • A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia
    • Cefalu AB, Pirruccello JP, Noto D, et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33: 2021–5.
    • (2013) Arterioscler Thromb Vasc Biol , vol.33 , pp. 2021-2025
    • Cefalu, A.B.1    Pirruccello, J.P.2    Noto, D.3
  • 133
    • 77953893410 scopus 로고    scopus 로고
    • Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia
    • Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010; 139: 149–53.
    • (2010) Gastroenterology , vol.139 , pp. 149-153
    • Amaro, A.1    Fabbrini, E.2    Kars, M.3
  • 134
    • 77149168465 scopus 로고    scopus 로고
    • Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease
    • Dongiovanni P, Valenti L, Rametta R, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 267–73.
    • (2010) Gut , vol.59 , pp. 267-273
    • Dongiovanni, P.1    Valenti, L.2    Rametta, R.3
  • 135
    • 84929266699 scopus 로고    scopus 로고
    • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
    • Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956–65.
    • (2015) Lancet , vol.385 , pp. 956-965
    • Neuschwander-Tetri, B.A.1    Loomba, R.2    Sanyal, A.J.3
  • 136
    • 78651260799 scopus 로고    scopus 로고
    • Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
    • Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17: 55–63.
    • (2011) Nat Med , vol.17 , pp. 55-63
    • Holland, W.L.1    Miller, R.A.2    Wang, Z.V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.